To grow their bottom lines, companies invest in business value drivers. This thesis examined whether multidimensional sustainability performance could be one of those drivers in the pharmaceutical industry. There are currently very few (if any) mandatory requirements for integrating multidimensional sustainability. Nor are there standardized methods of integrating, measuring, or communicating multidimensional sustainability. This thesis reviewed, compared, and contrasted (also known as benchmarking) voluntary sustainability initiatives and pharmaceutical company sustainability initiatives. The results were as follows: 1) the concept of multidimensional sustainability is generally understood; 2) integrating multidimensional sustainability is the morally and ethically correct action for pharmaceutical companies to take; 3) research is insufficient to support the relationship between integrating sustainability and driving business value in the pharmaceutical industry; and 4) pharmaceutical companies taking action to integrate multidimensional sustainability are reaping significant business value added. This thesis also discusses the reasons for and methods of measuring and reporting multidimensional sustainability performance, the elements required for successful integration of multidimensional sustainability in the pharmaceutical industry, and the steps necessary to integrate multidimensional sustainability throughout a pharmaceutical company.
Library of Congress Subject Headings
Pharmaceutical industry--Environmental aspects; Sustainable development
Department, Program, or Center
Civil Engineering Technology Environmental Management and Safety (CAST)
Jung, Thea, "Making a business case for integrating multidimensional sustainability in the pharmaceutical industry" (2002). Thesis. Rochester Institute of Technology. Accessed from
RIT – Main Campus